/ESTA
ESTA Stock - Establishment Labs Holdings Inc.
Healthcare|Medical - DevicesNASDAQ
$74.42+6.93%
+$4.83 (+6.93%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).60
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+4.8%upside
Target: $77.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ESTA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$73.67 – $75.16
TARGET (TP)$78.00
STOP LOSS$68.46
RISK/REWARD1:0.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.02
52W High$78.24
52W Low$26.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $166.03M | $165.15M | $161.70M | $126.68M | $84.68M |
| Gross Profit | $109.53M | $106.98M | $106.59M | $85.40M | $52.50M |
| Gross Margin | 66.0% | 64.8% | 65.9% | 67.4% | 62.0% |
| Operating Income | $-49,987,000 | $-65,026,000 | $-39,658,000 | $-25,140,000 | $-27,916,000 |
| Net Income | $-84,596,000 | $-78,502,000 | $-75,209,000 | $-41,139,000 | $-38,121,000 |
| Net Margin | -51.0% | -47.5% | -46.5% | -32.5% | -45.0% |
| EPS | $-3.00 | $-3.07 | $-3.08 | $-1.72 | $-1.63 |
Company Overview
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
75%
Hold / Neutral
2
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish2 Neutral/Bearish
Price Targets
$72
Average Target
↓ 2.8% Downside
Now
$48
Low
$72
Average
$107
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 20th 2025 | Canaccord Genuity | Initiation | Buy | $60 |
| May 16th 2025 | BTIG Research | Initiation | Buy | $62 |
| May 14th 2025 | Needham | Upgrade | Buy | $48 |
| April 14th 2025 | Needham | Initiation | Hold | - |
| May 22nd 2024 | Citigroup | Downgrade | Neutral | $60 |
| August 31st 2023 | JP Morgan | Initiation | Overweight | $75 |
| June 29th 2023 | Citigroup | Initiation | Buy | $79 |
| October 14th 2022 | Stephens | Resumed | Overweight | $90 |
| October 13th 2022 | Mizuho | Initiation | Buy | $70 |
| August 24th 2022 | B. Riley Securities | Initiation | Buy | $107 |
Earnings History & Surprises
ESTABeat Rate
56%
Last 18 quarters
Avg Surprise
-13.3%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$-0.38
Q4 2025
EPS Surprise History
Q1 24
+13.2%
$-0.79vs$-0.91
Q2 24
+13.4%
$-0.58vs$-0.67
Q3 24
-21.6%
$-0.62vs$-0.51
Q4 24
+3.3%
$-0.59vs$-0.61
Q1 25
-53.1%
$-0.98vs$-0.64
Q2 25
+15.7%
$-0.70vs$-0.83
Q3 25
-5.6%
$-0.57vs$-0.54
Q4 25
+29.6%
$-0.38vs$-0.54
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.22 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.54 | $-0.38 | +29.6% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.54 | $-0.57 | -5.6% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.83 | $-0.70 | +15.7% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.64 | $-0.98 | -53.1% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.61 | $-0.59 | +3.3% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.51 | $-0.62 | -21.6% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.67 | $-0.58 | +13.4% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.91 | $-0.79 | +13.2% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.80 | $-1.12 | -40.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.72 | $-0.65 | +9.7% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.68 | $-0.48 | +29.4% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.68 | $-0.55 | +19.1% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.54 | $-0.76 | -40.7% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.42 | $-0.90 | -114.3% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.38 | $-0.24 | +36.8% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.33 | $-0.60 | -81.8% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.35 | $-0.61 | -74.3% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $-0.28 | $-0.22 | +21.4% | ✓ BEAT |
Latest News
Canaccord Genuity Maintains Buy on Establishment Labs Hldgs, Raises Price Target to $85
📈 PositiveBenzinga•Dec 17, 2025, 07:45 PM•Also:
JP Morgan Maintains Overweight on Establishment Labs Hldgs, Raises Price Target to $80
📈 PositiveBenzinga•Dec 17, 2025, 07:22 PM
Mizuho Maintains Outperform on Establishment Labs Hldgs, Raises Price Target to $90
📈 PositiveBenzinga•Dec 17, 2025, 12:58 PM
Citigroup Maintains Neutral on Establishment Labs Hldgs, Raises Price Target to $75
➖ NeutralBenzinga•Dec 11, 2025, 09:00 PM•Also:
Needham Maintains Buy on Establishment Labs Hldgs, Raises Price Target to $84
📈 PositiveBenzinga•Dec 10, 2025, 12:31 PM
BTIG Maintains Buy on Establishment Labs Hldgs, Raises Price Target to $81
📈 PositiveBenzinga•Nov 14, 2025, 11:39 AM
JP Morgan Maintains Overweight on Establishment Labs Hldgs, Raises Price Target to $71
📈 PositiveBenzinga•Nov 6, 2025, 09:45 PM
Canaccord Genuity Maintains Buy on Establishment Labs Hldgs, Raises Price Target to $72
📈 PositiveBenzinga•Nov 6, 2025, 08:02 PM•Also:
Mizuho Maintains Outperform on Establishment Labs Hldgs, Raises Price Target to $85
📈 PositiveBenzinga•Nov 6, 2025, 12:19 PM
Needham Maintains Buy on Establishment Labs Hldgs, Raises Price Target to $70
📈 PositiveBenzinga•Nov 6, 2025, 10:11 AM
Establishment Labs Holding shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY25 revenue guidance above estimates. Also, BTIG raised its price target on the stock from $62 to $70.
📈 PositiveBenzinga•Nov 5, 2025, 05:31 PM
BTIG Maintains Buy on Establishment Labs Hldgs, Raises Price Target to $70
📈 PositiveBenzinga•Nov 5, 2025, 05:21 PM
Establishment Labs Hldgs FY2025 Revenue expected to be more than $210.000M vs $208.864M Est
📈 PositiveBenzinga•Nov 5, 2025, 01:05 PM
Establishment Labs Hldgs Q3 EPS $(0.38) Beats $(0.54) Estimate, Sales $53.782M Beat $52.011M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 01:02 PM
Establishment Labs Publishes Mia Femtech 3-Year Prospective Study Results In Aesthetic Surgery Journal
📈 PositiveBenzinga•Oct 14, 2025, 12:09 PM
Canaccord Genuity Initiates Coverage On Establishment Labs Hldgs with Buy Rating, Announces Price Target of $60
📈 PositiveBenzinga•Aug 20, 2025, 10:31 AM•Also: ,
Establishment Labs rises as Needham upgrades on easing trade war
📈 PositiveSeeking Alpha•May 14, 2025, 02:18 PM
Frequently Asked Questions about ESTA
What is ESTA's current stock price?
Establishment Labs Holdings Inc. (ESTA) is currently trading at $74.42 per share. The stock has moved +6.93% today.
What is the analyst price target for ESTA?
The average analyst price target for ESTA is $78.00, based on 1 analyst.
What sector is Establishment Labs Holdings Inc. in?
Establishment Labs Holdings Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is ESTA's market cap?
Establishment Labs Holdings Inc. has a market capitalization of $2.16 billion, making it a mid-cap company.
Does ESTA pay dividends?
No, Establishment Labs Holdings Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAHCO
AdaptHealth Corp.
$9.97
Mkt Cap: $1.4B
AZTA
Azenta, Inc.
$34.43
Mkt Cap: $1.6B
CNMD
CONMED Corporation
$39.95
Mkt Cap: $1.2B
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
$27.32
Mkt Cap: $1.6B
NVCR
NovoCure Limited
$12.84
Mkt Cap: $1.4B
SSII
SS Innovations International, Inc.
$5.72
Mkt Cap: $1.1B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
TDOC
Teladoc Health, Inc.
$7.23
Mkt Cap: $1.3B
UFPT
UFP Technologies, Inc.
$229.40
Mkt Cap: $1.8B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to ESTA for comparison